U.S. FDA approves Cepheid’s COVID-19 test to expand frontline testing
Category: #health  By Saipriya Iyer  Date: 2020-03-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

U.S. FDA approves Cepheid’s COVID-19 test to expand frontline testing

The U.S. FDA (Food and Drug Administration) has recently approved Cepheid’s COVID-19 test in response to the public health emergency caused by the coronavirus. The new test can help expand the availability of frontline testing in clinics and hospitals, without the need for round-tripping to a diagnostic lab. The federal agency has been rapidly focusing on granting emergency use authorization to tests and equipment to address the accelerating spread of the virus in the United States.

COVID-19 test of Cepheid has a distinct advantage over other tests, as it functions with or without the use of nasal swabs. This is considered advantageous because the nasal swabs supplies have been taxed globally. The new tests will be shipped out by the company from next week. The test, which is molecular and PCR-based, also has high level of accuracy as that of the lab-based testing in various U.S. facilities. However, it adopts Cepheid’s GeneXpert machine, which is a diagnostic kit, to ensure on-site delivery of results.

Nearly 23,000 GeneXpert micro-labs of the American molecular diagnostic company have reportedly been adopted across the world, with over 5,000 that are based in the U.S. Cepheid’s hardware has been running flu-related tests since many years and has high reliability rates.

The testing capacity in the U.S. has been increased in the past few weeks owing to widespread efforts to enhance its availability and cater to the hard-hit regions such as NYC by coronavirus pandemic. However, the demand for tests is rising continuously and this limited availability has resulted in only severe cases, with proof of elevated risk or confirmed contract tracing, being tested.

In order to effectively inform any coronavirus mitigation strategies, various testing solutions similar to that of Cepheid and other potential and accurate testing alternatives that can be carried out at home, such as the forthcoming antibodies test introduced by Scanwell, etc. are needed to expand the testing capabilities to the highest degree.

Source credit:

https://finance.yahoo.com/news/type-covid-19-test-now-134500434.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
By Saipriya Iyer

Boehringer Ingelheim, a pharmaceutical company, has recently announced the enrollment of 1st patient in its Phase 3 InPedILD™ trial. The trial will evaluate the dose and safety profile of nintedanib among childre...

Medtronic to turn Hyderabad into R&D hub with $160.3M investment
Medtronic to turn Hyderabad into R&D hub with $160.3M investment
By Saipriya Iyer

Medtronic, a medical device company, has reportedly announced an investment of Rs.1,200 crore ($160.3 million) to turn Hyderabad into its R&D center outside the U.S. The investment has been planned by the company s...

Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
By Saipriya Iyer

Toshiba, a Japanese multinational conglomerate, has reportedly made an exit from the laptop business and transferred its remaining minority stake in the PC business to Sharp. This will mark the company’s terminat...